FDA Approves Otsuka and Lundbeck's ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults | Illinois

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Apr 27, 2023--

Related Keywords

California ,United States ,Bonn ,Nordrhein Westfalen ,Germany ,Japan ,Tokyo ,Italy ,Thailand ,France ,Denmark ,American ,John Kraus ,Johan Luthman ,Statesjeffrey Gilbert ,Statesdyana Lescohier ,Statesrobert Murphy ,Otsuka America Pharmaceutical Inc ,American Psychiatric Association ,Otsuka Pharmaceutical Development Commercialization Inc ,Co Ltd ,Otsuka Pharmaceutical Co Ltd ,Otsuka Holdings Co Ltd ,Drug Administration ,H Lundbeck ,Otsuka Pharmaceutical Company Ltd ,Psychopharmacology Institute ,Twitter ,World Health Organization ,Linkedin ,National Institute Of Mental Health ,Roserm Mental Health ,Lundbeck ,National Pregnancy Registry For Atypical Antipsychotics ,Corporate Communications ,America Pharmaceutical ,New Drug Application ,Important Safety Information ,National Pregnancy Registry ,Otsuka America Pharmaceutical ,Otsuka Pharmaceutical Development ,Otsuka Pharmaceutical Company ,National Institute ,Patients With Bipolar ,Neuropsychiatr Dis ,Acting Injectable Antipsychotics ,United Statesrobert ,United Statesjeffrey ,United Statesdyana ,Business Wire ,Illinois ,